Adonis Georgiades at the Economist conference: Failure of doctors who have ‘composed’ oncology

The doctors who systematically wrote oncology medicine which failed in the III phase of clinical trials, blamed from the step of Economist Impact, the , . In his speech at the Economist conference, Health Minister, Adonis Georgiades, initially referred to the progress of science in the treatment of cancer, which – as he said – has been achieved in the last 10 years and has “surprised him”, as he said: “10 years ago the patients were doomed to end up. Now with the new drugs from leading companies that have managed to produce treatments that are truly innovative, they manage to give not only hope to patients, but also a very good quality of life for a number of years. This is amazing, because for the first time humanity can say that we are facing and fighting cancer and that is something wonderful,” he said. At the same time, however, as the currency said, it has two sides, as “budget overruns” are often noted, due to “incalculable use of innovative drugs”, as he stressed. This results in very large companies avoiding giving such drugs to Greece, meaning because of the mechanism of automatic returns. “And so when someone really needs such a drug, they won’t be able to find it. And that’s our failure, 100% ours. Our responsibility is when a patient really needs a medicine to save his life to be able to provide it.” Adonis Georgiades: ‘Doctor failure’ means the sub-composition of an exact drug that failed in clinical trials’ However, the doctors also have a great responsibility for this, noted the minister and referred to the case of Relyvrio, the very expensive innovative oncological drug for neuromyopathy, which was “written in our homeland unstoppable and sorodon, a very expensive treatment”, as he said. However, this drug proved ineffective in phase III of the tests and the manufacturing company is now planning its withdrawal. “Last year, it cost the system 15m euros. Only this year in the first two months of ’24 has it cost more than 3 million euros and the day before that drug which had not been approved EMA, it had only been approved FDA phase 2, not even phase 3, and yet they were writing it, it was withdrawn from the company as failures to pass phase 3 and therefore as a drug ultimately not working. But we found out it doesn’t work after we’ve spent tens of millions. This is a failure not of ministers, this is a failure of doctors. A great failure, which could not be prevented from setting rules themselves, to isolate bad colleagues. Not everyone wrote it. I’ve seen now who wrote it by name, most people didn’t write it. I want to make it clear that we need to establish very strict rules from now on about how these drugs will be administered and prescribed. In particular, because here the treatments do not cost like Relyvrio, 75,000 euros but cost 700,000 euros. And so if we follow the same model, we’ve all hailed together, we won’t even have aspirin. So we have to deal. The Association of Oncologists and Mrs. Gervidakis themselves and her colleagues were impressive at our meetings, very responsible and I thank them for that,” the Minister of Health stressed. The National Action Plan and the National Register of Neoplasms The Minister of Health also referred to the National Register of Neoplasms, which was one of the first to sign as Minister of Health, and his success depends on the cooperation of all involved. Regarding the National Action Plan for Cancer, the minister pledged that his term would be linked to its implementation. For Greece, said Mr Georgiadis, dealing with cancer is a top priority, as for all health systems. “We have no time to waste, we must run,” the minister said. He made special reference to the prevention programs “S. Doxiadis” implemented through the Recovery Fund, saying that for the first time the State is seriously involved in prevention. Zenia Saridaki, oncologist, Chairman of the Board of Directors, Hellenic Society of Medical Oncology (HeSMO), Director, 1st Oncology Department, Metropolitan Hospital Athens & Asklepios Diagnosis Crete, referred to the signing of the National Register of Neoplasms made in the first month of Adoni Georgiades at the Ministry of Health, saying that we are now entering a phase of implementation. It referred to the steps to be taken, such as in the therapeutic protocols, prescription oncology drugs by qualified doctors and placed particular emphasis on biomarkers. Precision medicine is valuable and is not expensive, he said, announcing that the Greek Society of Medical Oncology will present a reasoned legal proposal to the Ministry of Health. Since 2011 they have been invested by the pharmaceutical industry over 6m euros in biomarkers, so that oncology patients have these indicators, which are necessary, free of charge, he said. He also spoke about the continuous education of ecologists and the cooperation of the Greek Society of Medical Oncology with foreign universities. George Kapetanakis, president of the Greek Cancer Federation (ELLOK), said that from the beginning of the year we started with increased speed and two fixed demands from the oncological community such as the National Action Plan and the Neoplasms Register that are high on the priorities of the Ministry of Health. “Our country is in a creative mobility,” he said and stressed that the development of a National Action Plan aims to maximize the benefit for the patient. It will put the man at the center, using all the data. The National Action Plan is a State commitment and investment in the treatment of cancer starting with prevention, stressing that the National Plan should include ensuring equal access for patients to prevention, diagnosis and treatment. The elimination of inequalities must be a priority. Quality in patient-focused care is the second challenge, said Mr. Kapetanakis, and talked about the creation of integrated cancer treatment centres. Investment in innovation and cooperation between all stakeholders is a key factor in the success of an Action Plan. Also, the integration of modern technologies that revolutionize the treatment of cancer must be exploited. Furthermore, the search for new resources and the optimal distribution of existing resources and the adoption of evaluation indicators should be included. Mike Holmes, vice president, World Medical and Scientific Affairs Oncology Therapeutic Area, MSD Global, referred to the great scientific progress made over the last 20 years but also to changes made at the level of perceptions, saying features that the stigma for cancer has been significantly reduced. We need to do more, he said, because cancer remains a major challenge to public health. To make cancer from a deadly disease in years, he said, expressing the belief that this can be done with everyone’s cooperation. source: – Reportage: Janna Soulaki